How has been the historical performance of Biogen Pharma?
Biogen Pharma has experienced significant financial fluctuations, with net sales dropping to zero by March 2025 after a modest increase in previous years, while total expenditures rose sharply and profitability turned negative. Despite these challenges, shareholder funds increased, and cash flow from financing activities remained positive.
Answer:The historical performance of Biogen Pharma shows significant fluctuations in its financial metrics over the years.Breakdown:
Biogen Pharma's net sales have remained at zero from March 2023 to March 2025, following a modest increase to 2.47 crore in March 2022 from 1.62 crore in March 2021. Other operating income peaked at 2.38 crore in March 2024 but dropped to zero in March 2025. Total operating income followed a similar trend, reaching 2.16 crore in March 2022 before declining to zero by March 2025. The company faced a total expenditure of 1.13 crore in March 2025, a significant increase from 0.45 crore in March 2024, while operating profit (PBDIT) turned negative at -0.29 crore in March 2025, contrasting with a profit of 1.93 crore in March 2024. Profit before tax also fell to -0.29 crore in March 2025 from 1.93 crore in the previous year. The company's reserves have been negative, reaching -9.03 crore in March 2025, and shareholder's funds increased to 91.93 crore in March 2025 from 56.52 crore in March 2024. Cash flow from operating activities was negative at -1.00 crore in March 2025, while cash flow from financing activities showed a positive inflow of 35.00 crore. Overall, Biogen Pharma's financial performance has been marked by instability, with recent years showing a decline in sales and profitability, despite an increase in cash reserves.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
